Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Oncology Division Revenues [legacy 2023–2024 tag] by Year
Oncology Division Revenues [legacy 2023–2024 tag] ($M) ($M)
Pfizer Oncology Division Revenues [legacy 2023–2024 tag]: $11,567M in FY2024, up 36.9% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2024
11,567
Period ended Dec 31, 2024
Change on a year earlier
+36.9%
8,450 in FY2023
History
3 years
Since FY2022
Sources
1
Form 10-K (filed 2025-02-27)
Where the FY2024 figure comes from
Source: Form 10-K (filed 2025-02-27) ↗
Reported in Form 10-K Segment Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Oncology Division Revenues [legacy 2023–2024 tag] ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 11,567 | +36.9% | Form 10-K (filed 2025-02-27) ↗ |
| FY2023 | Dec 31, 2023 | 8,450 | -1.5% | Form 10-K (filed 2025-02-27) ↗ |
| FY2022 | Dec 31, 2022 | 8,583 | – | Form 10-K (filed 2025-02-27) ↗ |
Cite this data
StockData. (2026). Pfizer Oncology Division Revenues [legacy 2023–2024 tag] ($M), annual FY2022–FY2024 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/div-leg-onc-div
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.